Overview
- UCLH and UCL presented early results at the EULAR Congress in London in early June showing five of six patients given the lower dose of obecabtagene autoleucel (obe‑cel) entered remission within months.
- The treatment uses a patient’s own T cells engineered to target CD19 on B cells, causing deep B‑cell depletion followed by return of mainly early‑stage B cells consistent with an “immune reset.”
- Nine patients aged 12–65 with severe, treatment‑refractory lupus were treated on the trial with two dose levels so investigators could compare responses.
- Patients reported large improvements in symptoms and organ function and many were able to stop long‑term steroids and other immunosuppressant drugs after a single infusion.
- Investigators caution the data are from a very small cohort with limited follow‑up, especially for the three higher‑dose patients, so larger and longer studies are needed to confirm how long remissions last and to assess safety and infection risk.